A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.
Ontology highlight
ABSTRACT: PEGylation is routinely used to extend the systemic circulation of various protein therapeutics and nanomedicines. Nonetheless, mounting evidence is emerging that individuals exposed to select PEGylated therapeutics can develop antibodies specific to PEG, i.e., anti-PEG antibodies (APA). In turn, APA increase both the risk of hypersensitivity to the drug as well as potential loss of efficacy due to accelerated blood clearance of the drug. Despite the broad implications of APA, the timescales and systemic specificity by which APA can alter the pharmacokinetics and biodistribution of PEGylated drugs remain not well understood. Here, we developed a physiologically based pharmacokinetic (PBPK) model designed to resolve APA's impact on both early- and late-phase pharmacokinetics and biodistribu
SUBMITTER: Talkington AM
PROVIDER: S-EPMC9080587 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA